Loading…
Loading…
The Commission cleared, under EU State aid rules (Article 107(3)(c) TFEU), a €47 million direct grant from Germany to Vetter Pharma — a privately held CDMO headquartered in Ravensburg (Baden-Württemberg) that specialises in aseptic fill-finish of injectable drugs (pre-filled syringes, cartridges, vials) for pharma and biotech clients. The grant funds part of the first construction phase of a new manufacturing site in Saarlouis, Saarland, with total first-phase investment of roughly €480 million.
The Commission's clearance rationale cites regional-development objectives for Saarland (a former coal/steel region undergoing industrial transition) and alignment with the EU Pharmaceutical Strategy for Europe, which frames onshoring of injectable/sterile fill-finish capacity as a medicines-security priority following COVID-era supply disruptions. Vetter expects the site to create up to 2,000 jobs long-term; construction is slated to start Q2 2026 with operations targeted for 2031.
injectables is a capacity-constrained, specialised segment of pharma manufacturing; a new large-scale EU site adds onshore capacity that reduces reliance on non-EU CDMOs for this step of the supply chain.
of EU semiconductor "first-of-a-kind facility" clearances (Chips Act) but applied to pharmaceutical manufacturing under the Pharmaceutical Strategy framing — a signal the Commission is willing to approve single-company capacity grants in strategic-health-sector manufacturing, not just chips or batteries.
to a region historically dependent on coal/steel, consistent with EU cohesion/just-transition state-aid criteria cited in the decision.
state budget lines, or co-financed via an EU instrument — not disclosed in the Commission press release.
million construction phase.
as the site scales toward full 2031 operations.